Keyword: Strimvelis

Vivet Therapeutics

Vivet is harnessing the power of gene therapy to target Wilson disease and other rare genetic disorders as it looks to shake off a tough few years for research and sales in the gene therapy field.

10. GlaxoSmithKline

GlaxoSmithKline has one of the lowest R&D budgets in percentage of revenue terms of its peers; although its research budget was slightly up on 2015, this is still markedly down from the around £4 billion it was spending in 2012-13.

Ex-GSK rare disease head moves to Genenta

Carlo Russo has joined a growing list of ex-GlaxoSmithKline staffers moving into biotech after working on and helping launch the Big Pharma’s rare disease drug Strimvelis, although he does edge closer back to his old company.